Royce & Associates LP Raises Stock Position in Supernus Pharmaceuticals, Inc. $SUPN

Royce & Associates LP grew its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 385.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 197,737 shares of the specialty pharmaceutical company’s stock after purchasing an additional 156,972 shares during the period. Royce & Associates LP’s holdings in Supernus Pharmaceuticals were worth $9,828,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Hantz Financial Services Inc. increased its stake in shares of Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 281 shares during the period. Torren Management LLC purchased a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $49,000. Smartleaf Asset Management LLC increased its stake in shares of Supernus Pharmaceuticals by 30.8% during the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 268 shares during the period. Global Retirement Partners LLC increased its stake in shares of Supernus Pharmaceuticals by 532.4% during the fourth quarter. Global Retirement Partners LLC now owns 1,404 shares of the specialty pharmaceutical company’s stock worth $70,000 after buying an additional 1,182 shares during the period. Finally, Vestcor Inc purchased a new stake in shares of Supernus Pharmaceuticals during the third quarter worth approximately $67,000.

Analysts Set New Price Targets

A number of analysts recently weighed in on SUPN shares. Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 23rd. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Friday, March 27th. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $62.17.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, Director Frederick M. Hudson sold 5,369 shares of the stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $50.61, for a total value of $271,725.09. Following the transaction, the director directly owned 60,413 shares in the company, valued at $3,057,501.93. This represents a 8.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Padmanabh P. Bhatt sold 50,000 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $50.28, for a total value of $2,514,000.00. Following the completion of the sale, the vice president directly owned 17,044 shares of the company’s stock, valued at $856,972.32. The trade was a 74.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 116,406 shares of company stock valued at $5,911,086. Company insiders own 8.80% of the company’s stock.

Supernus Pharmaceuticals Stock Down 2.4%

Shares of Supernus Pharmaceuticals stock opened at $46.64 on Thursday. The firm has a market capitalization of $2.71 billion, a P/E ratio of -91.45, a P/E/G ratio of 1.03 and a beta of 0.57. Supernus Pharmaceuticals, Inc. has a 52 week low of $30.83 and a 52 week high of $59.68. The firm’s 50 day moving average is $49.84 and its two-hundred day moving average is $49.58.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.